argenx FIRST LOOK: A First Miss for Vyvgart, Negative ITP Read-Out
argenx' anticipated readout for ADVANCE-SC in the blood disease ITP turns out negative, as efficacy in the treatment arm drops below the (remarkably high) placebo rate. As a result, Vyvgart misses the stringent primary endpoint of sustained platelet count response, but also fails across other secondary endpoints. We deem no approval to come for ITP in the US and Europe in the near term now, and take these out of our SOTP. Consequently, we adjust our TP from € 495 to € 485, while maintaining a Buy rating.Argenx N.V. is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Utilizing its suite of differentiated technologies, Co. is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.